1
|
Chen LA, Yu YH, Tian WT, Lin WC, Grauffel C, Wu CY, Chen CL, Lim C, Chu HM, Chang TW, Peng CJ. Site-specific Conjugation of 6 DOTA Chelators to a CA19-9-targeting scFv-Fc Antibody for Imaging and Therapy. J Med Chem 2023; 66:10604-10616. [PMID: 37462154 PMCID: PMC10424180 DOI: 10.1021/acs.jmedchem.3c00753] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2023] [Indexed: 08/11/2023]
Abstract
Antibodies conjugated with diagnostic/therapeutic radionuclides are attractive options for inoperable cancers lacking accurate imaging methods and effective therapeutics, such as pancreatic cancer. Hence, we have produced an antibody radionuclide conjugate termed TE-1132 comprising a α-CA19-9 scFv-Fc that is site-specifically conjugated at each C-terminus to 3 DOTA chelators via a cysteine-containing peptide linker. The smaller scFv-Fc size facilitates diffusivity within solid tumors, whereas the chelator-to-antibody ratio of six enabled 177Lu-radiolabeled TE-1132 to exhibit high radioactivity up to 520 MBq/nmol. In mice bearing BxPC3 tumors, immuno-SPECT/CT imaging of [111In]In-TE-1132 and the biodistribution of [177Lu]Lu-TE-1132 showed selective tumor accumulation. Single and multiple doses of [177Lu]Lu-TE-1132 effectively inhibited the BxPC3 tumor growth and prolonged the survival of mice with no irreversible body weight loss or hematopoietic damage. The adequate pharmacokinetic parameters, prominent tumor accumulation, and efficacy with good safety in mice encourage the further investigation of theranostic TE-1132 for treating pancreatic cancer.
Collapse
Affiliation(s)
- Li-An Chen
- Immunwork,
Inc., Academia Rd., Sec.
1, Nangang, Taipei 11571, Taiwan
| | - Yueh-Hsiang Yu
- Immunwork,
Inc., Academia Rd., Sec.
1, Nangang, Taipei 11571, Taiwan
| | - Wei-Ting Tian
- Immunwork,
Inc., Academia Rd., Sec.
1, Nangang, Taipei 11571, Taiwan
| | - Wei-Chen Lin
- Immunwork,
Inc., Academia Rd., Sec.
1, Nangang, Taipei 11571, Taiwan
| | - Cédric Grauffel
- Immunwork,
Inc., Academia Rd., Sec.
1, Nangang, Taipei 11571, Taiwan
| | - Chun-Yi Wu
- Department
of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University, Beitou, Taipei 112, Taiwan
| | - Chuan-Lin Chen
- Department
of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University, Beitou, Taipei 112, Taiwan
| | - Carmay Lim
- Institute
of Biomedical Sciences, Academia Sinica, Academia Road, Taipei 115, Taiwan
| | - Hsing-Mao Chu
- Immunwork,
Inc., Academia Rd., Sec.
1, Nangang, Taipei 11571, Taiwan
| | - Tse-Wen Chang
- Immunwork,
Inc., Academia Rd., Sec.
1, Nangang, Taipei 11571, Taiwan
| | - Chi-Jiun Peng
- Immunwork,
Inc., Academia Rd., Sec.
1, Nangang, Taipei 11571, Taiwan
| |
Collapse
|
2
|
Grünberg J, Jeger S, Sarko D, Dennler P, Zimmermann K, Mier W, Schibli R. DOTA-functionalized polylysine: a high number of DOTA chelates positively influences the biodistribution of enzymatic conjugated anti-tumor antibody chCE7agl. PLoS One 2013; 8:e60350. [PMID: 23565233 PMCID: PMC3614955 DOI: 10.1371/journal.pone.0060350] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2012] [Accepted: 02/25/2013] [Indexed: 11/18/2022] Open
Abstract
Site-specific enzymatic reactions with microbial transglutaminase (mTGase) lead to a homogenous species of immunoconjugates with a defined ligand/antibody ratio. In the present study, we have investigated the influence of different numbers of 1,4,7,10-tetraazacyclododecane-N-N′-N′′-N′′′-tetraacetic acid (DOTA) chelats coupled to a decalysine backbone on the in vivo behavior of the chimeric monoclonal anti-L1CAM antibody chCE7agl. The enzymatic conjugation of (DOTA)1-decalysine, (DOTA)3-decalysine or (DOTA)5-decalysine to the antibody heavy chain (via Gln295/297) gave rise to immunoconjugates containing two, six or ten DOTA moieties respectively. Radiolabeling of the immunoconjugates with 177Lu yielded specific activities of approximately 70 MBq/mg, 400 MBq/mg and 700 MBq/mg with increasing numbers of DOTA chelates. Biodistribution experiments in SKOV3ip human ovarian cancer cell xenografts demonstrated a high and specific accumulation of radioactivity at the tumor site for all antibody derivatives with a maximal tumor accumulation of 43.6±4.3% ID/g at 24 h for chCE7agl-[(DOTA)-decalysine]2, 30.6±12.0% ID/g at 24 h for chCE7agl-[(DOTA)3-decalysine]2 and 49.9±3.1% ID/g at 48 h for chCE7agl-[(DOTA)5-decalysine)]2. The rapid elimination from the blood of chCE7agl-[(DOTA)-decalysine]2 (1.0±0.1% ID/g at 24 h) is associated with a high liver accumulation (23.2±4.6% ID/g at 24 h). This behavior changed depending on the numbers of DOTA moieties coupled to the decalysine peptide with a slower blood clearance (5.1±1.0 (DOTA)3 versus 11.7±1.4% ID/g (DOTA)5, p<0.005 at 24 h) and lower radioactivity levels in the liver (21.4±3.4 (DOTA)3 versus 5.8±0.7 (DOTA)5, p<0.005 at 24 h). We conclude that the site-specific and stoichiometric uniform conjugation of the highly DOTA-substituted decalysine ((DOTA)5-decalysine) to an anti-tumor antibody leads to the formation of immunoconjugates with high specific activity and excellent in vivo behavior and is a valuable option for radioimmunotherapy and potentially antibody-drug conjugates (ADCs).
Collapse
Affiliation(s)
- Jürgen Grünberg
- Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen, Switzerland
| | - Simone Jeger
- Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen, Switzerland
| | - Dikran Sarko
- Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
| | - Patrick Dennler
- Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen, Switzerland
| | - Kurt Zimmermann
- Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen, Switzerland
| | - Walter Mier
- Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
| | - Roger Schibli
- Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen, Switzerland
- * E-mail:
| |
Collapse
|
4
|
Abstract
Monoclonal antibodies can now be genetically engineered and endowed with new properties. In the future, gene technology could enable antigen-binding fragments to be made by exploiting repertoires of variable domain genes derived from immunized animals and expressed in bacteria. How readily can this approach be extended to production of 'in vitro' repertoires of variable domain genes, and obviate the immunization of animals?
Collapse
|
5
|
Smith W, Gore VA, Brandon DR, Lynch DN, Cranstone SA, Corvalan JR. Suppression of well-established tumour xenografts by a hybrid-hybrid monoclonal antibody and vinblastine. Cancer Immunol Immunother 1990; 31:157-63. [PMID: 2186853 PMCID: PMC11038217 DOI: 10.1007/bf01744730] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/1989] [Accepted: 11/21/1989] [Indexed: 12/30/2022]
Abstract
The hybrid-hybrid monoclonal antibody 28-19-8 has specificity for the tumour-associated antigen carcinoembryonic antigen and the vinca alkaloids. This bifunctional antibody has been used to target unmodified vinblastine sulphate to well-established MAWI human tumour xenografts implanted in nude mice. The highly significant suppression of tumour growth achieved throughout treatment has also been sustained for over 2 months after the withdrawal of treatment. Histological examination of excised tumours from treated animals has shown profound changes in their morphology when compared with tumours from control animals. Cells in tumours that had started to grow again after withdrawal of therapy were shown still to express carcinoembryonic antigen, the target antigen recognised by the bispecific antibody.
Collapse
Affiliation(s)
- W Smith
- Lilly Research Centre Ltd, Eli Lilly & Co., Windlesham, Surrey, United Kingdom
| | | | | | | | | | | |
Collapse
|
6
|
Sheldon EL, Nagainis PA, Kung VT. Detection of total DNA with single-stranded DNA binding protein conjugates. Biochem Biophys Res Commun 1989; 165:474-80. [PMID: 2686650 DOI: 10.1016/0006-291x(89)91094-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
We have developed a rapid and sensitive method for total DNA measurement using single-stranded DNA binding protein from E coli conjugated with horseradish peroxidase or urease. To detect DNA, the sample is heated or alkali treated to denature the DNA and then filtered through nylon or nitrocellulose membranes. After the single-stranded DNA is bound to the membrane, single-stranded DNA binding protein enzyme-conjugate is incubated with the membrane. Next, the unbound conjugate is washed off the membrane and the bound conjugate detected colorimetrically. The assay can detect 10 pg of DNA in less than 3 hr. This method can be applied to the detection of DNA contamination in therapeutic proteins produced by recombinant DNA or hybridoma techniques.
Collapse
Affiliation(s)
- E L Sheldon
- Molecular Devices Corporation, Menlo Park, California 94025
| | | | | |
Collapse
|
7
|
Upeslacis J, Hinman L. Chapter 16. Chemical Modification of Antibodies for Cancer Chemotherapy. ANNUAL REPORTS IN MEDICINAL CHEMISTRY 1988. [DOI: 10.1016/s0065-7743(08)60844-1] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|